Leaderboards/Cancer Mechanisms and Therapy

Cancer Mechanisms and Therapy

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Md Entaz Bahar
Gyeongsang National University
2
Urszula N. Wasko
Revolution Medicines (United States)
3
Diana-Theodora Morgos
Carol Davila University of Medicine and Pharmacy
4
Xingyu Peng
Nanchang University
5
Matthew B. Maxwell
Salk Institute for Biological Studies
6
Simone Lubrano
University of California San Diego
7
Iker Ausejo‐Mauleon
Clinica Universidad de Navarra
8
Fernando J. de Miguel
Yale Cancer Center
9
Aanchal Rathi
Jamia Millia Islamia
10
Fine Aliyuda
Medway NHS Foundation Trust

Papers

1
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Nature|2024
175 cit.
2
Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in Gastric Cancer
International Journal of Molecular Sciences|2024
157 cit.
3
ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity
Cell|2024
112 cit.
4
FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma
Cancer Cell|2025
34 cit.
5
Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models
JCI Insight|2024
7 cit.
6
Publication in Cancer Research (2024) [2 citations, W4393089000]
Cancer Research|2024
2 cit.
7
The Micro-Structure of the Celiac Ganglia—A Two-Photon Microscopy Study on Parkinson’s Disease
Diagnostics|2025
2 cit.
8
Abstract B101: Tumor-selective inhibition of active RAS in pancreatic ductal adenocarcinoma
Cancer Research|2024
1 cit.
9
Publication in Neuro-Oncology (2024) [1 citation, W4399788020]
Neuro-Oncology|2024
1 cit.
10
Spotting the clues: cluster of differentiation—a perspective of immune response intertwined with dysautonomia in colon cancer – a prospective cohort study
Journal of Medicine and Life|2025
1 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Jason M. Sheltzer
Yale University
2
Aya Kobayashi
Wakayama Medical University
3
Christopher J. Giuliano
IIT@MIT
4
Zhenhai Yu
Weifang Medical University
5
Xingjie Gao
Tianjin Medical University
6
Diana C. Hargreaves
Salk Institute for Biological Studies
7
Yuanrong Cheng
Fudan University
8
Xiujun Chang
Capital Medical University
9
Ronald L. Chandler
Michigan State University
10
QiJiong Li
Sun Yat-sen University

Papers

1
Oncogene-like addiction to aneuploidy in human cancers
Science|2023
161 cit.
2
Genome-wide identification and analysis of prognostic features in human cancers
Cell Reports|2022
129 cit.
3
ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity
Cell|2024
112 cit.
4
Deubiquitination of MYC by OTUB1 contributes to HK2 mediated glycolysis and breast tumorigenesis
Cell Death and Differentiation|2022
99 cit.
5
Extensive protein dosage compensation in aneuploid human cancers
Genome Research|2022
88 cit.
6
Phosphorylation of PFKFB4 by PIM2 promotes anaerobic glycolysis and cell proliferation in endometriosis
Cell Death and Disease|2022
62 cit.
7
FDX1 enhances endometriosis cell cuproptosis via G6PD-mediated redox homeostasis
APOPTOSIS|2023
61 cit.
8
Collaboration between distinct SWI/SNF chromatin remodeling complexes directs enhancer selection and activation of macrophage inflammatory genes
Immunity|2024
34 cit.
9
PIK3CA mutation in endometriotic epithelial cells promotes viperin-dependent inflammatory response to insulin
Reproductive Biology and Endocrinology|2023
32 cit.
10
CRISPR-based functional profiling of the Toxoplasma gondii genome during acute murine infection
Nature Microbiology|2024
32 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
P. Andrew Futreal
Wellcome Sanger Institute
2
Pasi A. Jänne
Harvard University
3
Anton Berns
Oncode Institute
4
Charles W.M. Roberts
Harvard University
5
Kenneth C. Anderson
Dana-Farber Cancer Institute
6
Tak W. Mak
University Health Network
7
Paul B. Fisher
Virginia Commonwealth University
8
Neal Rosen
Memorial Sloan Kettering Cancer Center
9
Arul M. Chinnaiyan
University of Michigan
10
Jeffrey Settleman
Enzo Life Sciences (United States)

Papers

1
Mutations of the BRAF gene in human cancer
Nature|2002
10.7k cit.
2
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Science|2007
4.5k cit.
3
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Neoplasia|2004
3.7k cit.
4
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
New England Journal of Medicine|2013
3.4k cit.
5
The polycomb group protein EZH2 is involved in progression of prostate cancer
Nature|2002
2.7k cit.
6
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
New England Journal of Medicine|2003
2.6k cit.
7
Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTEN
Cell|1998
2.6k cit.
8
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
Cancer Research|2006
2.6k cit.
9
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
New England Journal of Medicine|2005
2.5k cit.
10
FADD, a novel death domain-containing protein, interacts with the death domain of fas and initiates apoptosis
Cell|1995
2.4k cit.

Reagents for Cancer Mechanisms and Therapy

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Thermo Fisher ScientificEvidence 65

Cyclin D1 Monoclonal Antibody (DCS-6), Biotin

Cited in 13 papers
#MA562366
View Evidence →
Thermo Fisher ScientificEvidence 65

Cyclin D1 Recombinant Rabbit Monoclonal Antibody (5D8)

Cited in 13 papers
#MA5-60676
View Evidence →
Cell Signaling TechnologyEvidence 65

Phospho-MCM2 (Ser139) Antibody

Cited in 13 papers
#8861$362
View Evidence →

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 65

CDK8 (D6M3J) Rabbit Monoclonal Antibody

Cited in 19 papers
#17395$161,351
View Evidence →
Thermo Fisher ScientificEvidence 65

Cyclin D1 Recombinant Rabbit Monoclonal Antibody (RM241)

Cited in 13 papers
#MA562110
View Evidence →
Thermo Fisher ScientificEvidence 65

Cyclin D1 Recombinant Rabbit Monoclonal Antibody (HL2219)

Cited in 13 papers
#MA5-56668
View Evidence →